Expert Insights On CGT Formulation

1. Risk Managing Through The Void Of ATMP Visible Particle Guidance 9/8/2026

   Regulators expect cell therapy manufacturers to prove they control for visible particles, but guidance remains notably quiet on the matter. Companies must get creative or risk clinical holds.

2. Engineering CAR T Cells With mRNA-LNPs: Applying Oncology Learnings To Allergic Diseases 9/4/2026

   Targeted lipid nanoparticles (LNPs) could deliver mRNA encoding a CAR directly to T cells inside a patient with allergic disease. The potential implications extend beyond a single allergic condition. 

3. Why Delivery Is Defining The Next Era Of Neuromuscular Therapeutics 8/19/2026

   Emerging therapies are being designed to safely deliver oligonucleotides to disease-relevant tissues. Delivery is no longer a technical hurdle to overcome but a strategic lever.

4. Building A Self-Driving Lab For LNP Development 7/20/2026

   With commercially available components, MIT researchers built a platform that accelerates LNP process development, optimization, and autonomous manufacturing research.

5. Addressing The Particulate Challenge In Cell Therapy Products 7/15/2026

   Cell therapy products challenge traditional particulate controls. One expert explains detection, mitigation, and contamination prevention.

6. Reassessing Nanoparticle Immunotoxicity: From Well-Established To Novel Approaches 7/14/2026

   This article highlights government-funded resources available to de-risk nanomedicines, reviews principles of immunotoxicity testing, and discusses emerging methodologies.

7. Enhancing Gene And Cell Therapies With Circular RNA-Based Gene Expression 6/29/2026

   While circular RNA platforms can enhance protein expression, developing effective delivery strategies remains the key challenge to achieving therapeutic efficacy.

8. Why Improving Drug Delivery Remains A Major Opportunity In Oncology 6/12/2026

   Engineered oncolytic viruses are emerging as a promising way to target tumors, deliver immune-stimulating payloads, and improve treatment of metastatic cancer.

9. Strategic Synthesis Of ASGCT And ASCO 2026 6/10/2026

   The spring 2026 conference season made one thing obvious to those of us watching the data: the artisan era of ex vivo cellular manufacturing is finally receding.

10. Spine Care Redefined: Autologous Cell Therapy For Degenerative Disc Disease 5/19/2026

    Autologous intradiscal therapy integrates delivery and biology into one system, highlighting the potential of cell therapies in complex, localized disease environments.